St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods

[1]  Carsten Denkert,et al.  Strategies for developing Ki67 as a useful biomarker in breast cancer. , 2015, Breast.

[2]  Florian Länger,et al.  The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer. , 2015, Human pathology.

[3]  M. Fernö,et al.  Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines – a Swedish survey with central re-assessment , 2015, Acta oncologica.

[4]  R. Gelber,et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R. Shui,et al.  An Interobserver Reproducibility Analysis of Ki67 Visual Assessment in Breast Cancer , 2015, PloS one.

[6]  B. Thürlimann,et al.  Standardization for Ki-67 Assessment in Moderately Differentiated Breast Cancer. A Retrospective Analysis of the SAKK 28/12 Study , 2015, PloS one.

[7]  T. Miyazaki,et al.  Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility , 2015, Journal of Clinical Pathology.

[8]  Carsten Denkert,et al.  Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study , 2014, Clinical Cancer Research.

[9]  A. Luini,et al.  Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes , 2014, Breast Cancer Research.

[10]  Mårten Fernö,et al.  A novel model for Ki67 assessment in breast cancer , 2014, Diagnostic Pathology.

[11]  S. Bull,et al.  Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information , 2014, Modern Pathology.

[12]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. Luini,et al.  Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  C. Perou,et al.  Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Anais Malpica,et al.  Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer , 2012, Histopathology.

[16]  S Michiels,et al.  Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Felipe C Geyer,et al.  Molecular Classification of Estrogen Receptor-positive/Luminal Breast Cancers , 2012, Advances in anatomic pathology.

[18]  Sunil R. Lakhani,et al.  WHO classification of tumours of the breast , 2012 .

[19]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[20]  Pierre-Marie Martin,et al.  Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review , 2011, Breast Cancer Research and Treatment.

[21]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  E Leonardi,et al.  Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies , 2011, Diagnostic pathology.

[23]  Mikael Lundin,et al.  Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer , 2011, BMC clinical pathology.

[24]  Mark T. W. Ebbert,et al.  A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer , 2010, Clinical Cancer Research.

[25]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[26]  Päivi Heikkilä,et al.  Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.

[27]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[28]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). , 2010, Archives of pathology & laboratory medicine.

[29]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Axel Hausen,et al.  Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers , 2009, Breast Cancer Research and Treatment.

[31]  J. Baak,et al.  Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  Consumer Protection,et al.  European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[34]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[37]  T. Decker,et al.  Standardisierte pathologische Untersuchung von Mamma-Exzisionspräparaten Relevanz innerhalb eines interdisziplinären Praxisprotokolls für das Qualitätsmanagement der brusterhaltenden Therapie , 1997, Der Pathologe.

[38]  T. Decker,et al.  [Standardized pathologic examination of breast excision specimen. Relevance within an interdisciplinary practice protocol for quality management of breast saving therapy]. , 1997, Der Pathologe.

[39]  J. Peterse,et al.  Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. , 1992, Human pathology.